GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Philogen SpA (STU:78Q) » Definitions » Change In Payables And Accrued Expense

Philogen SpA (STU:78Q) Change In Payables And Accrued Expense : €0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Philogen SpA Change In Payables And Accrued Expense?

Philogen SpA's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2024 was €0.00 Mil. It means Philogen SpA's Accounts Payable & Accrued Expense stayed the same from Jun. 2024 to Dec. 2024 .

Philogen SpA's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was €0.00 Mil. It means Philogen SpA's Accounts Payable & Accrued Expense stayed the same from Dec. 2023 to Dec. 2024 .

Philogen SpA Change In Payables And Accrued Expense Historical Data

The historical data trend for Philogen SpA's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Philogen SpA Change In Payables And Accrued Expense Chart

Philogen SpA Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Change In Payables And Accrued Expense
- - - - -

Philogen SpA Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Philogen SpA Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Philogen SpA Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Philogen SpA's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Philogen SpA Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Philogen SpA (STU:78Q) » Definitions » Change In Payables And Accrued Expense
Comparable Companies
MIL:UBM MIL:ARBS VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX SMMT RPRX OCSE:GMAB XKRX:196170 INCY HKSE:02269 INSM HKSE:01801
Traded in Other Exchanges
PHIL:Italy 78Q:Germany
Address
Piazza La Lizza No. 7, Siena, ITA, 53100
Website
https://www.philogen.com
Philogen SpA is a biotechnology company. The company develops biotech products for the imaging and therapy of life-threatening diseases. The company's focus is predominantly related to oncology drug development, although the company has also brought products for the treatment of chronic inflammatory diseases to the clinic. Its pipeline products include Nidlegy; Fibromun; Darleukin; Dodekin; Dekavil and others. Geographically, the company operates in the European Union, Switzerland, and the United States of America.

Philogen SpA Headlines

No Headlines